Vitiligo Epidemiology

• In 2025, the 7MM accounted for more than 11 million prevalent cases of vitiligo, including approximately 5 million male and 6 million female cases. The prevalent patient pool is projected to increase through 2036, primarily driven by population growth, improved disease recognition and diagnosis, and the persistence of a substantial affected population requiring long-term management.
• In 2025, non-segmental vitiligo accounted for more than 4 million cases in EU4 and the UK, establishing its position as the most prevalent type linked to the condition.
• Female predominance is evident across several vitiligo datasets, with women comprising a higher share of diagnosed cases in multiple populations, potentially reflecting differences in healthcare-seeking behavior, diagnosis, or underlying disease susceptibility; however, the strength of this pattern varies by geography.
• The global consensus distinguishing nonsegmental (generalized) and segmental vitiligo has established a unified classification framework, enhancing diagnostic precision and prognostic clarity. By categorizing segmental vitiligo as a distinct entity with unilateral distribution and rapid onset, and grouping nonsegmental vitiligo under the umbrella term vitiligo. This harmonized terminology reduces diagnostic ambiguities.
• The reported prevalence of vitiligo and its associated psychosocial comorbidities varies substantially across studies, largely due to differences in study populations, geographic settings, assessment instruments, and diagnostic definitions. Despite this variability, epidemiological evidence indicates a substantial disease burden, with more than half of patients reported to experience one or more psychosocial comorbidities, including depression, anxiety, social phobia, stigmatization, adjustment disorders, sleep disturbances and emotional impairment.

DelveInsight’s “Vitiligo – Epidemiology Forecast – 2036” report delivers an in depth understanding of vitiligo, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Geography Covered 

North America: The United States

Europe: Germany, France, Italy, Spain and the United Kingdom

Asia-Pacific: Japan 

Vitiligo- Understanding 

Vitiligo Overview and Diagnosis

Vitiligo, also known as leucoderma, is a chronic depigmenting skin disorder that causes the formation of discolored patches of skin. Also, hair on these skin regions can lose pigment and appear white. This condition is characterized by the selective loss of melanocytes—cells responsible for imparting color to skin, leading to pigment dilution in the affected areas of the skin. The affected skin then turns into typical nonscaly, chalky-white macules. It is the most common depigmenting skin disorder. The average age of onset of vitiligo is in the mid-twenties, but it can appear at any age. Once affected, the size and number of patches vary from one person to another.

The diagnosis of vitiligo does not require confirmatory laboratory tests in most cases, irrespective of its clinical subtype. Dermatologists often diagnose vitiligo based solely on a physical examination. Doctors may suggest a skin biopsy or blood test if they need more information about the mechanism of the condition affecting skin cells. In vivo, confocal microscopy (noninvasive) or a skin biopsy using specific markers can assess the absence of melanocytes from lesions. No screening methods are available for vitiligo. The clinical screening of associated disorders in diagnosing vitiligo is a debatable topic. Wood’s lamp examination of vitiligo reveals a chalky white enhancement of depigmented skin, while hypopigmented skin is not enhanced. 

Further details are provided in the report.

Vitiligo Epidemiology

Key Findings from Vitiligo Epidemiological Analysis and Forecast 

• According to DelveInsight’s analysis, the US had nearly 5 million prevalent cases of vitiligo in 2025, and it is projected to rise in the coming years.
• In 2025, females accounted for approximately 60% cases and males accounted for almost 40% cases of Vitiligo in 7MM.
• In Japan in 2025, vitiligo cases are highest in the 0–11 years age group (approximately 150,000 cases), followed by the 30–39 years group (about 100,000 cases), while the lowest burden is observed in the 50–59 years group (around 60,000 cases), indicating a relatively higher impact in early life.

              Patient Share (%) Distribution of Vitiligo by Countries in the 7MM in 2025

Industry Experts and Physician Views for Vitiligo 

To keep up with vitiligo dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the epidemiology in vitiligo, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights at country level. Centers such as the The Warren Alpert Medical School of Brown University, Rutgers University, Philadelphia College of Osteopathic Medicine, Paris-Est Créteil University etc. were contacted. 

Their opinion helps understand, validate, highlight and provide epidemiological context in vitiligo.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of vitiligo, explaining their causes, signs and symptoms and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along diagnostic guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Report Insights

Vitiligo Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year forecast 
• Patient Burden Trends (by geography)
• The 7MM Coverage 

FAQs

Epidemiology Insights

• What is the forecast period covered in the report?
• How is epidemiological data collected and analyzed for forecasting purposes?
• Out of all EU4 countries and the UK, which country had the highest population of vitiligo cases?
• What are the disease risks and burdens of vitiligo? 
• At what compound annual growth rate the population is expected to grow across the 7MM during the forecast period?
• What would be the forecasted patient population of vitiligo at the 7MM level?

Reasons to Buy

• Insights on vitiligo burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the vitiligo epidemiology analysis and patient population trends.